These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 36697138)

  • 1. Thromboprophylaxis in Patients With Fontan Circulation.
    Van den Eynde J; Possner M; Alahdab F; Veldtman G; Goldstein BH; Rathod RH; Hoskoppal AK; Saraf A; Feingold B; Alsaied T
    J Am Coll Cardiol; 2023 Jan; 81(4):374-389. PubMed ID: 36697138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. No difference between aspirin and warfarin after extracardiac Fontan in a propensity score analysis of 475 patients.
    Iyengar AJ; Winlaw DS; Galati JC; Wheaton GR; Gentles TL; Grigg LE; Justo RN; Radford DJ; Attard C; Weintraub RG; Bullock A; Sholler GS; Celermajer DS; d'Udekem Y;
    Eur J Cardiothorac Surg; 2016 Nov; 50(5):980-987. PubMed ID: 27229665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term outcomes of warfarin versus aspirin after Fontan surgery.
    Attard C; Monagle PT; d'Udekem Y; Mackay MT; Briody J; Cordina R; Hassan EB; Simm P; Rice K; Ignjatovic V;
    J Thorac Cardiovasc Surg; 2021 Oct; 162(4):1218-1228.e3. PubMed ID: 33563422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of Major Bleeding in Patients With Atrial Fibrillation Treated With Non-Vitamin K Antagonist Oral Anticoagulants Compared With Warfarin in Clinical Practice (from Phase II of the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation [ORBIT-AF II]).
    Steinberg BA; Simon DN; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Kowey PR; Mahaffey KW; Peterson ED; Piccini JP;
    Am J Cardiol; 2017 May; 119(10):1590-1595. PubMed ID: 28363354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-Vitamin K Antagonist Oral Anticoagulants and Antiplatelet Therapy for Stroke Prevention in Patients With Atrial Fibrillation: A Meta-Analysis of Randomized Controlled Trials.
    Kumar S; Danik SB; Altman RK; Barrett CD; Lip GY; Chatterjee S; Roubin GS; Natale A; Danik JS
    Cardiol Rev; 2016; 24(5):218-23. PubMed ID: 26274538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative effectiveness among thromboprophylaxis strategies after the Fontan operation: A systematic review and network meta-analysis.
    Sethasathien S; Phinyo P; Sittiwangkul R; Silvilairat S
    Thromb Res; 2024 Jul; 241():109093. PubMed ID: 39003950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strategies for thromboprophylaxis in Fontan circulation: a meta-analysis.
    Alsaied T; Alsidawi S; Allen CC; Faircloth J; Palumbo JS; Veldtman GR
    Heart; 2015 Nov; 101(21):1731-7. PubMed ID: 26319122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes in a Warfarin-Treated Population With Atrial Fibrillation.
    Björck F; Renlund H; Lip GY; Wester P; Svensson PJ; Själander A
    JAMA Cardiol; 2016 May; 1(2):172-80. PubMed ID: 27437888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation With Hypertrophic Cardiomyopathy: A Nationwide Cohort Study.
    Jung H; Yang PS; Jang E; Yu HT; Kim TH; Uhm JS; Kim JY; Pak HN; Lee MH; Joung B; Lip GYH
    Chest; 2019 Feb; 155(2):354-363. PubMed ID: 30472021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the New Oral Anticoagulants and Warfarin in Patients with Atrial Fibrillation and Valvular Heart Disease: Systematic Review and Meta-Analysis.
    de Souza Lima Bitar Y; Neto MG; Filho JAL; Pereira LV; Travassos KSO; Akrami KM; Roever L; Duraes AR
    Drugs R D; 2019 Jun; 19(2):117-126. PubMed ID: 31055767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative Stroke, Bleeding, and Mortality Risks in Older Medicare Patients Treated with Oral Anticoagulants for Nonvalvular Atrial Fibrillation.
    Graham DJ; Baro E; Zhang R; Liao J; Wernecke M; Reichman ME; Hu M; Illoh O; Wei Y; Goulding MR; Chillarige Y; Southworth MR; MaCurdy TE; Kelman JA
    Am J Med; 2019 May; 132(5):596-604.e11. PubMed ID: 30639551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulant and Warfarin in Cirrhotic Patients With Nonvalvular Atrial Fibrillation.
    Lee HF; Chan YH; Chang SH; Tu HT; Chen SW; Yeh YH; Wu LS; Kuo CF; Kuo CT; See LC
    J Am Heart Assoc; 2019 Mar; 8(5):e011112. PubMed ID: 30834802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness and safety of non-vitamin K antagonist oral anticoagulants in patients with hypertrophic cardiomyopathy with non-valvular atrial fibrillation.
    Lin Y; Xiong H; Su J; Lin J; Zhou Q; Lin M; Zhao W; Peng F
    Heart Vessels; 2022 Jul; 37(7):1224-1231. PubMed ID: 35041061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Chronic Kidney Disease Stage G4: A Single-Center Experience.
    Heleniak Z; Papuga-Szela E; Krzysztof P; Anetta U
    J Cardiovasc Pharmacol; 2020 Dec; 76(6):671-677. PubMed ID: 33284572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anticoagulation Therapy After the Fontan Procedure.
    Miwa K; Iwai S; Nagashima T
    Pediatr Cardiol; 2022 Aug; 43(6):1271-1276. PubMed ID: 35217887
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome.
    Bala MM; Celinska-Lowenhoff M; Szot W; Padjas A; Kaczmarczyk M; Swierz MJ; Undas A
    Cochrane Database Syst Rev; 2020 Oct; 10(10):CD012169. PubMed ID: 33045766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interrupted or Uninterrupted Oral Anticoagulants in Patients Undergoing Atrial Fibrillation Ablation.
    Yang P; Wang C; Ye Y; Huang T; Yang S; Shen W; Xu G; Wu Q
    Cardiovasc Drugs Ther; 2020 Jun; 34(3):371-381. PubMed ID: 32232617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of Ischemic Stroke, Major Bleeding, and Other Adverse Events With Warfarin Use vs Non-vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation With a History of Intracranial Hemorrhage.
    Tsai CT; Liao JN; Chiang CE; Lin YJ; Chang SL; Lo LW; Hu YF; Tuan TC; Chung FP; Chao TF; Lip GYH; Chen SA
    JAMA Netw Open; 2020 Jun; 3(6):e206424. PubMed ID: 32478848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Oral Anticoagulants in Older Adult Patients With Atrial Fibrillation: Pairwise and Network Meta-Analyses.
    Wang X; Wang T; Chen X; Tian W; Ma D; Zhang J; Li Q; Chen Z; Ju J; Xu H; Chen K
    J Am Med Dir Assoc; 2023 Aug; 24(8):1233-1239.e26. PubMed ID: 37355246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Prior Gastrointestinal Bleeding.
    Kwon S; Lee SR; Choi EK; Lee E; Jung JH; Han KD; Cha MJ; Oh S; Lip GYH
    Stroke; 2021 Jan; 52(2):511-520. PubMed ID: 33412904
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.